Business Context and Reporting Period
Pavmed Inc. (PAVM) filed a Form 8-K on January 21, 2026, reporting a significant corporate governance event regarding its listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing is a Current Report (Item 8.01) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material change reported is the restoration of compliance with Nasdaq listing requirements:
- Regained Compliance: On January 21, 2026, the Company received notification from Nasdaq that it regained compliance with the $1 minimum bid price requirement (Listing Rule 5550(a)(2)).
- Compliance Period: Compliance was achieved as the closing bid price remained at or above $1 per share from January 2, 2026, through January 19, 2026.
- Previous Status: The Company had previously been notified on January 23, 2025, of non-compliance due to a closing bid price below $1 for 30 consecutive business days ending January 22, 2025.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No new risks or contingencies were disclosed in this specific report, other than the historical context of the prior delisting warning which has now been resolved.
Investor Verification Checklist
- Verify the current trading price of PAVM on Nasdaq to ensure continued compliance with the $1 minimum bid price.
- Review the Company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains none.
- Monitor future Nasdaq communications to confirm no new compliance issues arise.